Application Note: Anti-AML1-ETO Antibody has been tested in ChIP, ELISA and Western Blots. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 80 kDa in the appropriate cell lysate or extract.
Concentration Value: neat
ELISA Dilution: 1:500
ChIP Dilution: 4 μl/ChIP
Western Blot Dilution: 1:1,000
General Disclaimer Note: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Immunogen: Anti-AML1-ETO Antibody was produced in rabbits by repeated immunizations with a synthetic peptide of human AML1-ETO.
Physical State: Liquid (sterile filtered)
Purity and Specificity: Anti-AML1-ETO Antibody is monospecific antiserum processed by delipidation and defibrination followed by sterile filtration. This product reacts with human AML1-ETO. Cross reactivity with AML1-ETO from other sources is not known.
Background: This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22. This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Anti-AML1-ETO Antibody is ideal for research in Cancer and Gene Expression.
Low Endotoxin: No
English
Deutsch
